Arctic Vision Announces Expansion of License Territory for ARVN001

16 August 2021 | Monday | News

Arctic Vision Announces Expansion of License Territory for Suprachoroidal Space Injection Therapy ARVN001 to Include ASEAN Countries and India
Image Source : retinatoday

Image Source : retinatoday

Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced today the entering of an amendment to the exclusive license agreement with its partner Clearside Biomedical, Inc. (Nasdaq: CLSD) ("Clearside"), to expand the licensed territory for ARVN001 (triamcinolone acetonide suprachoroidal injectable suspension, known as XIPERE™ in the U.S.) from Greater China (mainland ChinaHong KongMacau and Taiwan) and South Korea to also include ASEAN Countries (BruneiCambodiaIndonesiaLaosMalaysiaMyanmarthe PhilippinesSingaporeThailand, and Vietnam) and India.

ARVN001 is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the suprachoroidal space (SCS®) through Clearside's patented SCS Microinjector®. The product is being investigated for the treatment of macular edema associated with uveitis ("UME"). In the U.S., Clearside's XIPERE New Drug Application filing was accepted in May 2021 by the Food and Drug Administration. In China, Arctic Vision is planning to initiate a Phase III clinical trial in the 2nd half of the year.

Dr. Eddy (Hoi Ti) Wu, Founder, CEO and Board Director of Arctic Vision, commented: "We are very excited to expand the license territory of ARVN001 in Asia, as well as our relationship with Clearside. Building our commercial reach into the pan-Asia market has always been a major strategic goal, and this amendment accelerates the process. Beginning with ARVN001, we strive to bring innovative eyecare solutions to the greater Asian market."

"We are pleased to expand our relationship with Arctic Vision." said George Lasezkay, Pharm.D., J.D., President and CEO, Clearside Biomedical. "For more than a year, the two companies have worked closely together and made great progress. We appreciate Arctic Vision's strong capabilities in clinical development and commercialization to bring this innovative treatment option to patients in the region suffering with UME."



Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in